<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitropoulos, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Kiroudi-Voulgari, A.</style></author><author><style face="normal" font="default" size="100%">Zervas, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, C.</style></author><author><style face="normal" font="default" size="100%">Logothetis, C. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Neoadjuvant cisplatin and interferon-α2B in the treatment and organ preservation of penile carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cisplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">interferon alfa-2B</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-alpha</style></keyword><keyword><style  face="normal" font="default" size="100%">penile neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1994</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028168456&amp;partnerID=40&amp;md5=9d63ef51e32caf00d6ead9cc509be83a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">152</style></volume><pages><style face="normal" font="default" size="100%">1124 - 1126</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">We investigated the antitumor activity and toxicity of cisplatin and interferon-α2B as the primary treatment of penile carcinoma. A total of 13 consecutive patients with nonmetastatic, histologically confirmed invasive squamous cell carcinoma of the penis underwent treatment consisting of 20 mg./m.2 cisplatin intravenously and 5 x 106 μ./m.2 interferon-α2B subcutaneously daily for 5 consecutive days. An equivalent dose of interferon was then administered subcutaneously every 2 days for 3 weeks and the regimen was repeated at 28-day intervals. Of 12 evaluable patients 9 responded: 4 achieved a pathologically confirmed complete remission of 38+, 21+, 10 and 7 months in duration (2 with relapse were treated with local therapy and remain with no evidence of disease), and 5 achieved a partial response, underwent surgical removal of residual disease and remained disease-free for 14+ to 24+ months. The most significant toxicities were anemia in 5 patients and reversible renal impairment in 3 but no patient had neutropenic fever or required platelet transfusion. We conclude that primary treatment with cisplatin and interferon-α2B induced responses in 75% of 12 patients with penile carcinoma and allowed for a less radical operation than originally scheduled. A larger number of patients and longer followup will be required to confirm these encouraging preliminary results.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :16Export Date: 21 February 2017</style></notes></record></records></xml>